Research programme: neural progenitor based cell therapies - Eyestem
Latest Information Update: 08 Nov 2024
Price :
$50 *
At a glance
- Originator Eyestem
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 25 Sep 2024 Preclinical trials in Parkinson's disease in India (Parenteral) (Eyestem pipeline, September 2024)